| (Values in U.S. Thousands) | Sep, 2021 | Jun, 2021 | Mar, 2021 | Sep, 2020 | Jun, 2020 |
| Sales | 0 | 10 | 0 | 33 | 0 |
| Sales Growth | -100.00% | unch | -100.00% | unch | -100.00% |
| Net Income | -19,316 | -18,399 | -10,862 | 113,658 | -50,525 |
| Net Income Growth | -4.98% | -69.39% | -109.56% | +324.95% | +3.60% |
Trillium Therapeutics Inc (TRIL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.
Fiscal Year End Date: 12/31